Tandem Auto-Allo In Acute Myeloid Leukemia (AML) Patients In First Complete Remission (CR)

Review Series ADVANCES IN ACUTE MYELOID LEUKEMIA Hematopoietic stem cell transplantation for patients with AML in first complete remission

Although the majority of patients with acute myeloid leukemia (AML) enter remission upon induction chemotherapy, the risk of relapse is considerable. That risk varies greatly according to age and genetic subtype as major denominators. Taking an increasingly detailed risk evaluation into account, the intensity and type of postremission therapy is generally tailored according to risk profile, whe...

the outcome of autologous stem cell transplantation in first complete remission acute myeloid leukemia patients- single center study

post-remission treatment in patients with acute myeloid leukemia is still controversial. one potent choice for patients with no donor available is autologous stem cell transplantation. the median follow-up period was 18 months and the median age was 26 years old. in the review of 116 recently diagnosed aml patients (except aml- m3) who underwent autologous stem cell transplantation, 72.4% of pa...

first complete remission versus other- than- first complete remission in acute myelogenous leukemia with allogeneic hematopoietic stem cell transplantation

introduction: the traditional goal of the treatment of acute myelogenous leukemia is to produce and maintain a complete remission (cr).the difference in survival time was entirely attributable to the duration of time spent in cr .in this study, the outcome of aml patients with allogeneic hsct in cr1 versus other than cr1 was compared. patients and methods: since march 1991 until november 2008, ...

Cooked and Noncooked Diets in Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Relapse and death during first remission in acute myeloid leukemia.

Many papers have discussed the advisability of administering intensive chemotherapy to older patients with untreated acute myeloid leukemia (AML). More specifically, several studies have attempted to identify patients at particularly high risk of induction death following such therapy. However, the issue of chemotherapy-induced death once patients are in complete remission (CR) has received les...